Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective validation of a hepatotoxicity prediction algorithm in IBD patients starting thiopurines
NL-OMON26269Not yet recruiting
- Sponsor
- n.a.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azathioprine and mercaptopurine in inflammatory bowel disease (IBD), sponsored by n.a. Primary endpoint: hepatotoxicity. Planned start Nov 2015; status: not yet recruiting.
02
Drugs
azathioprinemercaptopurine
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON26269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26269.